CLEVELAND, Oct. 16, 2018 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the company's MRIdian® and
MRIdian Linac – the world's only FDA-cleared MRI-guided radiation
therapy systems – will be featured at the Annual Meeting of the
American Society for Radiation Oncology (ASTRO). ASTRO 2018 will be
held October 21-24, 2018 in
San Antonio, TX and will include a
number of presentations highlighting the unique capabilities,
clinical experience and patient outcomes of ViewRay's MRIdian and
MRIdian Linac.
At ASTRO, ViewRay will highlight the four key elements that
differentiate MRIdian Linac from any other radiotherapy system on
the market today. These unique capabilities include:
- Visualization of the tumor and surrounding organs with
high-definition, high-contrast MR imaging (SEE)
- Daily on-table treatment adaptation to accommodate anatomical
positioning changes that regularly occur from one day of treatment
to the next (SHAPE)
- Real-time soft tissue image guidance and beam control during
radiation delivery (STRIKE)
- Ability to fit into existing standard linear accelerator vaults
(SIZE)
Visitors to the company's booth # 1121 can see these
one-of-a-kind features first-hand in an up-close simulated
MRI-guided ROAR™ (Real-time On-table Adaptive Radiotherapy) patient
treatment. ViewRay's booth will also feature presentations from
seven MRIdian users covering a spectrum of topics from
commissioning and re-contouring to novel applications and real-time
on-table adaptive therapy.
Two Industry Expert Theater sessions at ASTRO will highlight
imaging of tumor response and clinical outcomes using MRIdian
MRI-guided Radiotherapy. Related sessions include:
- "MRI-Guided Radiotherapy: Imaging of Tumor Response to
Therapy", to be held Sunday, October
21 from 2:45–3:45 p.m. with presentations by Carri
Glide-Hurst, Ph.D. (Henry Ford),
Nicola Dinapoli, M.D., Ph.D.
(Gemelli), and John Chetley Ford,
Ph.D. (University of Miami)
- "MRI-Guided Radiotherapy Clinical Outcomes: A Summary of
Prospective Trials" to be held Tuesday,
October 23 from 12:30–1:30 p.m. with presentations by
Michael Bassetti, M.D., Ph.D.
(University of Wisconsin), Imran Zoberi, M.D. (Washington University), and Amar Kishan, M.D. (UCLA)
As part of the ASTRO scientific sessions, an interactive panel
entitled "Current and Future Applications for MR-guided
Radiotherapy with Real-time Adaptive Radiotherapy" will be held on
Tuesday, October 23 from
1:00 p.m. - 2:30 p.m. to further
explore MR-guided radiotherapy implementation, early clinical
outcomes, and areas of future research. Early clinical experience
suggests that use of MRI-guided radiotherapy, particularly
utilizing on-table adaptive radiotherapy with daily assessment of
plan quality and optimization, may translate to a clinical benefit
in locally advanced pancreatic cancer, liver tumors and
oligometastatic disease. The panel will feature presentations from
Percy Lee, M.D. and Michael Steinberg, M.D. from UCLA, Olga Green,
Ph.D. from Washington University School
of Medicine in St. Louis, and
Benjamin Movsas, M.D. from Henry
Ford Health System.
For a full schedule of MRIdian-focused presentations and events
at ASTRO or to book a product demonstration, please visit
https://go.viewray.com/ASTRO_2018.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that potentially may arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with magnetic
resonance imaging capabilities, is intended to provide stereotactic
radiosurgery and precision radiotherapy for lesions, tumors, and
conditions anywhere in the body where radiation treatment is
indicated.
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. These statements are subject to risks
and uncertainties that could cause future results to differ
materially from those referenced. Forward looking statements
include, but are not limited to references to the presentations to
be featured at ASTRO and related clinical experience and patient
outcomes. Given these uncertainties, the reader is advised not to
place any undue reliance on any forward-looking statements.
Additional risk factors include, among others, the ability to raise
the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates, government
and regulatory uncertainty, including but not limited to obtaining
authorizations to market and new tariffs and trade restrictions,
and overall market conditions. These forward-looking statements are
made as of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/astro-2018-presentations-to-feature-unique-capabilities-and-clinical-outcomes-of-viewrays-mridian-next-generation-cancer-care-300730654.html
SOURCE ViewRay, Inc.